392 related articles for article (PubMed ID: 34314483)
41. [Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy].
Ptushkin VV; Kulagin AD; Lukina EA; Davydkin IL; Konstantinova TS; Shamrai VS; Minaeva NV; Kudlay DA; Gapchenko EV; Markova OA; Borozinets AY
Ter Arkh; 2020 Sep; 92(7):77-84. PubMed ID: 33346448
[TBL] [Abstract][Full Text] [Related]
42. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
43. Dosing Patterns of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab in the United States: A Retrospective Claims-Based Analysis.
Cheng WY; Fishman J; Yenikomshian M; Mahendran M; Kunzweiler C; Vu JD; Duh MS
Adv Ther; 2024 Jan; 41(1):413-430. PubMed ID: 37999832
[TBL] [Abstract][Full Text] [Related]
44. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
Peixoto VP; Prudêncio C; Vieira M
Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
[TBL] [Abstract][Full Text] [Related]
45. Different Levels of Incomplete Terminal Pathway Inhibition by Eculizumab and the Clinical Response of PNH Patients.
Harder MJ; Höchsmann B; Dopler A; Anliker M; Weinstock C; Skerra A; Simmet T; Schrezenmeier H; Schmidt CQ
Front Immunol; 2019; 10():1639. PubMed ID: 31379839
[No Abstract] [Full Text] [Related]
46. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
47. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
Xu B; Kang B; Chen J; Li S; Zhou J
Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
[TBL] [Abstract][Full Text] [Related]
48. Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.
Kelly RJ; Höchsmann B; Szer J; Kulasekararaj A; de Guibert S; Röth A; Weitz IC; Armstrong E; Risitano AM; Patriquin CJ; Terriou L; Muus P; Hill A; Turner MP; Schrezenmeier H; Peffault de Latour R
N Engl J Med; 2015 Sep; 373(11):1032-9. PubMed ID: 26352814
[TBL] [Abstract][Full Text] [Related]
49. Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Szer J; Hill A; Höchsmann B; Kulasekararaj A; Risitano AM; Van Den Neste E; Liljeholm M; Ebrahim KS; Bedrosian CL; Gao X; Ames D; Socié G
Am J Hematol; 2016 Mar; 91(3):E16-7. PubMed ID: 26690023
[No Abstract] [Full Text] [Related]
50. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
51. Hemolytic paroxysmal nocturnal hemoglobinuria: 20 years of medical progress.
Peffault de Latour R; Hosokawa K; Risitano AM
Semin Hematol; 2022 Jan; 59(1):38-46. PubMed ID: 35491057
[TBL] [Abstract][Full Text] [Related]
52. Long-term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2-year results from two pivotal phase 3 studies.
Kulasekararaj AG; Griffin M; Langemeijer S; Usuki K; Kulagin A; Ogawa M; Yu J; Mujeebuddin A; Nishimura JI; Lee JW; Peffault de Latour R;
Eur J Haematol; 2022 Sep; 109(3):205-214. PubMed ID: 35502600
[TBL] [Abstract][Full Text] [Related]
53. The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target.
Risitano AM; Frieri C; Urciuoli E; Marano L
Immunol Rev; 2023 Jan; 313(1):262-278. PubMed ID: 36110036
[TBL] [Abstract][Full Text] [Related]
54. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Muus P; Dührsen U; Risitano AM; Schubert J; Luzzatto L; Schrezenmeier H; Szer J; Brodsky RA; Hill A; Socié G; Bessler M; Rollins SA; Bell L; Rother RP; Young NS
Blood; 2007 Dec; 110(12):4123-8. PubMed ID: 17702897
[TBL] [Abstract][Full Text] [Related]
55. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
Schubert J; Hillmen P; Röth A; Young NS; Elebute MO; Szer J; Gianfaldoni G; Socié G; Browne P; Geller R; Rother RP; Muus P;
Br J Haematol; 2008 Jun; 142(2):263-72. PubMed ID: 18503589
[TBL] [Abstract][Full Text] [Related]
56. Eculizumab in pregnancy: a narrative overview.
Sarno L; Tufano A; Maruotti GM; Martinelli P; Balletta MM; Russo D
J Nephrol; 2019 Feb; 32(1):17-25. PubMed ID: 30159857
[TBL] [Abstract][Full Text] [Related]
57. No Good Deed Goes Unpunished: Eculizumab and Invasive Neisserial Infections.
McQuillen DP; Ram S
Clin Infect Dis; 2019 Aug; 69(4):601-603. PubMed ID: 30418552
[No Abstract] [Full Text] [Related]
58. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria.
Reiss UM; Schwartz J; Sakamoto KM; Puthenveetil G; Ogawa M; Bedrosian CL; Ware RE
Pediatr Blood Cancer; 2014 Sep; 61(9):1544-50. PubMed ID: 24777716
[TBL] [Abstract][Full Text] [Related]
60. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
